Skip to main content

REFILE-BRIEF-FDA Approves Regeneron's Dupixent For Children Aged 6-11 Yrs With Moderate-To-Severe Atopic Dermatitis

* FDA APPROVES DUPIXENT® (DUPILUMAB) AS FIRST BIOLOGIC MEDICINE FOR CHILDREN AGED 6 TO 11 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.